Tumor cell invasion of von Hippel Lindau renal cell carcinoma cells is mediated by membrane type-1 matrix metalloproteinase

Molecular Cancer

Volumn 5, Issue , 2006, Pages

  Petrella, Brenda L ^a   Brinckerhoff, Constance E ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MATRIX METALLOPROTEINASE 14; SMALL INTERFERING RNA; VON HIPPEL LINDAU PROTEIN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN CONTAINING PROTEIN 1; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; COLLAGEN DEGRADATION; CONTROLLED STUDY; DRUG TARGETING; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CARCINOMA; NUCLEOTIDE SEQUENCE; RNA INTERFERENCE; WILD TYPE; ENZYMOLOGY; GENE EXPRESSION REGULATION; KIDNEY TUMOR; METABOLISM; METASTASIS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; VON HIPPEL LINDAU DISEASE;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; COLLAGEN TYPE I; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MATRIX METALLOPROTEINASE 14; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RNA INTERFERENCE; VON HIPPEL-LINDAU DISEASE;

EID: 33846675525     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-5-66     Document Type: Article

References (71)

1. Jemal A Tiwari RC Murray T Ghafoor A Samuels A Ward E Feuer EJ Thun MJ Cancer statistics, 2004 CA Cancer J Clin 2004 54 8-29 14974761
2. Lam JS Shvarts O Leppert JT Figlin RA Belldegrun AS Renal cell carcinoma 2005: New frontiers in staging, prognostication and targeted molecular therapy J Urol 2005 173 1853-1862 10.1097/01.ju.0000165693.68449.c3 15879764
3. Motzer RJ Russo P Nanus DM Berg WJ Renal cell carcinoma Curr Probl Cancer 1997 21 185-232 10.1016/S0147-0272(97)80007-4 9285186
4. Motzer RJ Bander NH Nanus DM Renal-cell carcinoma N Engl J Med 1996 335 865-875 10.1056/NEJM199609193351207 8778606
5. Hes FJ van der Luijt RB Lips CJ Clinical management of Von Hippel-Lindau (VHL) disease Neth J Med 2001 59 225-234 10.1016/S0300-2977(01)00165-6 11705642
6. Linehan WM Walther MM Zbar B The genetic basis of cancer of the kidney J Urol 2003 170 2163-2172 10.1097/01.ju.0000096060.92397.ed 14634372
7. Goldman Cecil Textbook of Medicine, W.B. Saunders Company 22nd 2004
8. Barry RE Krek W The von Hippel-Lindau tumour suppressor: A multi-faceted inhibitor of tumourigenesis Trends Mol Med 2004 10 466-472 10.1016/ j.molmed.2004.07.008 15350900
9. Kim WY Kaelin WG Role of VHL gene mutation in human cancer J Clin Oncol 2004 22 4991-5004 10.1200/JCO.2004.05.061 15611513
10. Sufan RI Jewett MA Ohh M The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma Am J Physiol Renal Physiol 2004 287 F1-6 10.1152/ajprenal.00424.2003 15180922
11. Singh AD Shields CL Shields JA von Hippel-Lindau disease Surv Ophthalmol 2001 46 117-142 10.1016/S0039-6257(01)00245-4 11578646
12. Kaelin WG Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer Clin Cancer Res 2004 10 6290S-5S 10.1158/1078-0432.CCR-sup-040025 15448019
13. Maynard MA Ohh M Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer Am J Nephrol 2004 24-1 13 10.1159/000075346 14654728
14. Safran M Kaelin WG Jr. HIF hydroxylation and the mammalian oxygen-sensing pathway J Clin Invest 2003 111-779 783 153778 12639980 10.1172/JCI200318181
15. Semenza GL Targeting HIF-1 for cancer therapy Nat Rev Cancer 2003 3 721-732 10.1038/nrc1187 13130303
16. Iliopoulos O Kibel A Gray S Kaelin WG Jr. Tumour suppression by the human von Hippel-Lindau gene product Nat Med 1995 1 822-826 10.1038/ nm0895-822 7585187
17. Maxwell PH Wiesener MS Chang GW Clifford SC Vaux EC Cockman ME Wykoff CC Pugh CW Maher ER Ratcliffe PJ The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis Nature 1999 399 271-275 10.1038/20459 10353251
18. Hoffman MA Ohh M Yang H Klco JM Ivan M Kaelin WG Jr. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF Hum Mol Genet 2001 10 1019-1027 10.1093/hmg/10.10.1019 11331612
19. Maranchie JK Vasselli JR Riss J Bonifacino JS Linehan WM Klausner RD The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma Cancer Cell 2002 1 247-255 10.1016/ S1535-6108(02)00044-2 12086861
20. Kondo K Klco J Nakamura E Lechpammer M Kaelin WG Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein Cancer Cell 2002 1 237-246 10.1016/S1535-6108(02)00043-0 12086860
21. Kondo K Kim WY Lechpammer M Kaelin WG Jr. Inhibition of HIF2alpha Is Sufficient to Suppress pVHL-Defective Tumor Growth PLoS Biol 2003 1 E83 300692 14691554 10.1371/journal.pbio.0000083
22. Zimmer M Doucette D Siddiqui N Iliopoulos O Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors Mol Cancer Res 2004 2 89-95 14985465
23. Petrella BL Lohi J Brinckerhoff CE Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma Oncogene 2005 24 1043-1052 10.1038/sj.onc.1208305 15592504
24. Seiki M Membrane-type 1 matrix metalloproteinase: A key enzyme for tumor invasion Cancer Lett 2003 194 1-11 10.1016/S0304-3835(02)00699-7 12706853
25. Sternlicht MD Werb Z How matrix metalloproteinases regulate cell behavior Annu Rev Cell Dev Biol 2001 17 463-516 10.1146/ annurev.cellbio.17.1.463 11687497
26. Egeblad M Werb Z New functions for the matrix metalloproteinases in cancer progression Nat Rev Cancer 2002 2 161-174 10.1038/nrc745 11990853
27. Overall CM Lopez-Otin C Strategies for MMP inhibition in cancer: innovations for the post-trial era Nat Rev Cancer 2002 2 657-672 10.1038/ nrc884 12209155
28. McCawley LJ Matrisian LM Matrix metalloproteinases: They're not just for matrix anymore! Curr Opin Cell Biol 2001 13 534-540 10.1016/ S0955-0674(00)00248-9 11544020
29. Seiki M Yana I Roles of pericellular proteolysis by membrane type-1 matrix metalloproteinase in cancer invasion and angiogenesis Cancer Sci 2003 94 569-574 10.1111/j.1349-7006.2003.tb01484.x 12841863
30. Sounni NE Noel A Membrane type-matrix metalloproteinases and tumor progression Biochimie 2005 87 329-342 10.1016/j.biochi.2004.07.012 15781320
31. Kitagawa Y Kunimi K Uchibayashi T Sato H Namiki M Expression of messenger RNAs for membrane-type 1, 2, and 3 matrix metalloproteinases in human renal cell carcinomas J Urol 1999 162 905-909 10.1097/ 00005392-199909010-00088 10458406
32. Skubitz KM Skubitz AP Differential gene expression in renal-cell cancer J Lab Clin Med 2002 140 52-64 10.1067/mlc.2002.125213 12080328
33. Duffy MJ The role of proteolytic enzymes in cancer invasion and metastasis Clin Exp Metastasis 1992 10 145-155 10.1007/BF00132746 1582084
34. Koochekpour S Jeffers M Wang PH Gong C Taylor GA Roessler LM Stearman R Vasselli JR Stetler-Stevenson WG Kaelin WG Jr. Linehan WM Klausner RD Gnarra JR Vande Woude GF The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells Mol Cell Biol 1999 19 5902-5912 84441 10454537
35. Sato H Takino T Miyamori H Roles of membrane-type matrix metalloproteinase-1 in tumor invasion and metastasis Cancer Sci 2005 96 212-217 10.1111/j.1349-7006.2005.00039.x 15819718
36. Seiki M Koshikawa N Yana I Role of pericellular proteolysis by membrane-type 1 matrix metalloproteinase in cancer invasion and angiogenesis Cancer Metastasis Rev 2003 22 129-143 10.1023/ A:1023087113214 12784992
37. Datta K Nambudripad R Pal S Zhou M Cohen HT Mukhopadhyay D Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer J Biol Chem 2000 275 20700-20706 10.1074/jbc.M909970199 10748176
38. Kurban G Hudon V Duplan E Ohh M Pause A Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis Cancer Res 2006 66 1313-1319 10.1158/ 0008-5472.CAN-05-2560 16452184
39. Friedl P Wolf K Proteolytic and non-proteolytic migration of tumour cells and leucocytes Biochem Soc Symp 2003 277-285 14587300
40. Huntington JT Shields JM Der CJ Wyatt CA Benbow U Slingluff CL Jr. Brinckerhoff CE Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: Role of BRAF mutation and fibroblast growth factor signaling J Biol Chem 2004 279 33168-33176 10.1074/jbc.M405102200 15184373
41. Wyatt CA Geoghegan JC Brinckerhoff CE Short hairpin RNA-mediated inhibition of matrix metalloproteinase-1 in MDA-231 cells: Effects on matrix destruction and tumor growth Cancer Res 2005 65 11101-11108 10.1158/0008-5472.CAN-05-2446 16322260
42. Kamada M Suzuki K Kato Y Okuda H Shuin T von Hippel-Lindau protein promotes the assembly of actin and vinculin and inhibits cell motility Cancer Res 2001 61 4184-4189 11358843
43. Ohh M Yauch RL Lonergan KM Whaley JM Stemmer-Rachamimov AO Louis DN Gavin BJ Kley N Kaelin WG Jr. Iliopoulos O The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix Mol Cell 1998 1 959-968 10.1016/S1097-2765(00)80096-9 9651579
44. Bluyssen HA Lolkema MP van Beest M Boone M Snijckers CM Los M Gebbink MF Braam B Holstege FC Giles RH Voest EE Fibronectin is a hypoxia-independent target of the tumor suppressor VHL FEBS Lett 2004 556 137-142 10.1016/S0014-5793(03)01392-9 14706840
45. Hsu T Adereth Y Kose N Dammai V Endocytic function of von Hippel-Lindau tumor suppressor protein regulates surface localization of fibroblast growth factor receptor 1 and cell motility J Biol Chem 2006 281 12069-12080 10.1074/jbc.M511621200 16505488
46. Atkinson SJ Crabbe T Cowell S Ward RV Butler MJ Sato H Seiki M Reynolds JJ Murphy G Intermolecular autolytic cleavage can contribute to the activation of progelatinase A by cell membranes J Biol Chem 1995 270 30479-30485 10.1074/jbc.270.30.17797 8530478
47. Sato H Takino T Kinoshita T Imai K Okada Y Stetler Stevenson WG Seiki M Cell surface binding and activation of gelatinase A induced by expression of membrane-type-1-matrix metalloproteinase (MT1-MMP) FEBS Lett 1996 385 238-240 10.1016/0014-5793(96)00389-4 8647259
48. Strongin AY Collier I Bannikov G Marmer BL Grant GA Goldberg GI Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease J Biol Chem 1995 270 5331-5338 10.1074/jbc.270.10.5331 7890645
49. Kinoshita T Sato H Takino T Itoh M Akizawa T Seiki M Processing of a precursor of 72-kilodalton type IV collagenase/gelatinase A by a recombinant membrane-type 1 matrix metalloproteinase Cancer Res 1996 56 2535-2538 8653693
50. Polette M Birembaut P Membrane-type metalloproteinases in tumor invasion Int J Biochem Cell Biol 1998 30 1195-1202 10.1016/S1357-2725(98)00083-1 9839445
51. Staller P Sulitkova J Lisztwan J Moch H Oakeley EJ Krek W Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL Nature 2003 425 307-311 10.1038/nature01874 13679920
52. Hotary K Allen E Punturieri A Yana I Weiss SJ Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3 J Cell Biol 2000 149 1309-1323 10.1083/jcb.149.6.1309 10851027
53. Ueda J Kajita M Suenaga N Fujii K Seiki M Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: importance of MT1-MMP as a therapeutic target for invasive tumors Oncogene 2003 22 8716-8722 10.1038/sj.onc.1206962 14647466
54. Munoz-Najar UM Neurath KM Vumbaca F Claffey KP Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation Oncogene 2005
55. Nonaka T Nishibashi K Itoh Y Yana I Seiki M Competitive disruption of the tumor-promoting function of membrane type 1 matrix metalloproteinase/ matrix metalloproteinase-14 in vivo Mol Cancer Ther 2005 4 1157-1166 10.1158/1535-7163.MCT-05-0127 16093431
56. Soulie P Carrozzino F Pepper MS Strongin AY Poupon MF Montesano R Membrane-type-1 matrix metalloproteinase confers tumorigenicity on nonmalignant epithelial cells Oncogene 2005 24 1689-1697 10.1038/ sj.onc.1208360 15608664
57. Esteban-Barragan MA Avila P Alvarez-Tejado M Gutierrez MD Garcia-Pardo A Sanchez-Madrid F Landazuri MO Role of the von Hippel-Lindau tumor suppressor gene in the formation of beta1-integrin fibrillar adhesions Cancer Res 2002 62 2929-2936 12019174
58. Slaton JW Inoue K Perrotte P El-Naggar AK Swanson DA Fidler IJ Dinney CP Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma Am J Pathol 2001 158 735-743 11159211
59. Takahashi M Oka N Naroda T Nishitani MA Kanda K Kanayama HO Kagawa S Prognostic significance of matrix metalloproteinases-2 activation ratio in renal cell carcinoma Int J Urol 2002 9 531-538 10.1046/ j.1442-2042.2002.00516.x 12445230
60. Walther MM Kleiner DE Lubensky IA Pozzatti R Nyguen T Gnarra JR Hurley K Venzon D Linehan WM Stetler-Stevenson WG Progelatinase A mRNA expression in cell lines derived from tumors in patients with metastatic renal cell carcinoma correlates inversely with survival Urology 1997 50 295-301 10.1016/S0090-4295(97)00220-3 9255309
61. Seiki M Mori H Kajita M Uekita T Itoh Y Membrane-type 1 matrix metalloproteinase and cell migration Biochem Soc Symp 2003 253-262 14587298
62. Bae SN Arand G Azzam H Pavasant P Torri J Frandsen TL Thompson EW Molecular and cellular analysis of basement membrane invasion by human breast cancer cells in Matrigel-based in vitro assays Breast Cancer Res Treat 1993 24 241-255 10.1007/BF01833264 8435479
63. Staehler M Rohrmann K Haseke N Stief CG Siebels M Targeted agents for the treatment of advanced renal cell carcinoma Curr Drug Targets 2005 6 835-846 10.2174/138945005774574498 16305462
64. Maynard MA Ohh M Molecular targets from VHL studies into the oxygen-sensing pathway Curr Cancer Drug Targets 2005 5 345-356 10.2174/ 1568009054629672 16101382
65. Kaelin WG Jr. The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing Biochem Biophys Res Commun 2005 338 627-638 10.1016/ j.bbrc.2005.08.165 16153592
66. Shaheen PE Bukowski RM Emerging drugs for renal cell carcinoma Expert Opin Emerg Drugs 2005 10 773-795 10.1517/14728214.10.4.773 16262562
67. Gnarra JR Tory K Weng Y Schmidt L Wei MH Li H Latif F Liu S Chen F Duh FM Mutations of the VHL tumour suppressor gene in renal carcinoma Nat Genet 1994 7 85-90 10.1038/ng0594-85 7915601
68. Tian H McKnight SL Russell DW Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells Genes Dev 1997 11 72-82 9000051
69. Lohi J Lehti K Westermarck J Kahari VM Keski-Oja J Regulation of membrane-type matrix metalloproteinase-1 expression by growth factors and phorbol 12-myristate 13-acetate Eur J Biochem 1996 239 239-247 10.1111/j.1432-1033.1996.0239u.x 8706726
70. Student's t-test analysis http://www.physics.csbsju.edu/stats/t-test.html
71. Aimes RT Quigley JP Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments J Biol Chem 1995 270 11 5872-5876 10.1074/ jbc.270.11.5872 7890717